Added to YB: 2024-01-24
Pitch date: 2024-01-24
IMMX:US [bullish]
Immix Biopharma, Inc.
+70.9%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Market Cap
$427.9M
Pitch Price
$4.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.51
P/E
-10.44
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Show full summary:
Immix Biopharma, Inc. IMMX:US
A summary for this pitch has not been created yet.
Read full article (0 min)